<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HABE7F6E1C5B24387A69D27669DBF0F54" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 8405 IH: Protecting Access to Medication Abortion Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-07-18</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 8405</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220718">July 18, 2022</action-date><action-desc><sponsor name-id="B001224">Ms. Bush</sponsor> (for herself, <cosponsor name-id="B001292">Mr. Beyer</cosponsor>, <cosponsor name-id="O000173">Ms. Omar</cosponsor>, <cosponsor name-id="J000032">Ms. Jackson Lee</cosponsor>, <cosponsor name-id="M001143">Ms. McCollum</cosponsor>, and <cosponsor name-id="N000147">Ms. Norton</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To preserve access to abortion medications.</official-title></form><legis-body id="H190BA898472E48E4A3425C5717B25B62" style="OLC"><section id="H70AE5B44171B425BBDFD72D3BE40957F" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Protecting Access to Medication Abortion Act</short-title></quote>.</text></section><section id="HA00764F838B142B5A18706AA76799020"><enum>2.</enum><header>Modification of REMS</header><subsection id="HE3A8F87857B840ACA11A91E1FAA9B5BA"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services (referred to in this section as the <quote>Secretary</quote>) shall require the responsible person involved to submit a proposal under subsection (g)(4)(A) of section 505–1 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>) to modify the risk evaluation and mitigation strategy under such section that applies to mifepristone so that—</text><paragraph id="HE52271C49BB44EFA80E2F83AA9B7C7E1"><enum>(1)</enum><text display-inline="yes-display-inline">the in-person dispensing requirement is removed from such risk evaluation and mitigation strategy; </text></paragraph><paragraph id="HE5F9218477D0475CA81ED3B3E4494BB5"><enum>(2)</enum><text display-inline="yes-display-inline">patients may access prescriptions for such drug via telehealth; and</text></paragraph><paragraph id="HC6E4D3B94D3F4A71A4A7E14272AB0A2D"><enum>(3)</enum><text>all pharmacies that are certified to dispense such drug are permitted to, at minimum, dispense and mail such drug to patients.</text></paragraph></subsection><subsection id="H290456E3DFD942FF84E4F6CE2D563167"><enum>(b)</enum><header>Modifications</header><text>Nothing in subsection (a) shall be construed to prevent the Secretary from approving a modification to the risk evaluation and mitigation strategy for mifepristone based on sound scientific evidence and in accordance with section 505–1(h) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1(h)</external-xref>). Any modifications to such risk evaluation and mitigation strategy made after the proposal to modify required pursuant to subsection (a) shall be in accordance with the requirements under paragraphs (1), (2), and (3) of such subsection, unless the Secretary, based on sound scientific evidence and in accordance with section 505–1 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>), determines that a risk evaluation and mitigation strategy for mifepristone is no longer necessary. </text></subsection><subsection id="HC256FC0B9C5449289B2578A99DE676A5"><enum>(c)</enum><header>Clarification</header><text>Nothing in subsection (a) shall be construed to limit the authority of the Secretary to impose the requirements described in paragraphs (1), (2), and (3) of such subsection to a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>) for any drug other than mifepristone. </text></subsection><subsection id="HD6147BFEA86D4061A914D38A032265DC"><enum>(d)</enum><header>Definition</header><text>In this section, the term <term>mifepristone</term> means mifepristone that is—</text><paragraph id="H1181BE4CD9934B4F813C92706B6E2EF3"><enum>(1)</enum><text>approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>);</text></paragraph><paragraph id="HB130DCD9324D4287936EB093D6C28508"><enum>(2)</enum><text>indicated for medical abortion; and</text></paragraph><paragraph id="H07B9CFD734604BE59670A347AF42F018"><enum>(3)</enum><text>subject to a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>).</text></paragraph></subsection></section></legis-body></bill> 

